Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2023 Earnings Call Transcript
Cara Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were $-0.57.
Cara Therapeutics Inc. (CARA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Chescapmanager LLC Traci Lerner | 1,702,110 | $524,250 | 0.05% | |
| 2. | Farallon Capital Thomas Steyer | 1,556,251 | $479,325 | 0% | |
| 3. | Renaissance Technologies Jim Simons | 1,108,931 | $341,551 | +5% | 0% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 866,300 | $266,820 | +1% | 0% |
| 5. | Millennium Management Israel Englander | 587,909 | $181,076 | +1% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.19 | 500,000 | Large Shareholder | 3,568,057 | 2017-03-31 | Filing | |
| $4.93 | 247,727 | Director | 3,068,057 | 2016-03-17 | Filing | |
| $4.78 | 152,273 | Director | 2,820,330 | 2016-03-16 | Filing | |
| $4.93 | 247,727 | Large Shareholder | 3,068,057 | 2016-03-17 | Filing | |
| $4.78 | 152,273 | Large Shareholder | 2,820,330 | 2016-03-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.29 | 3,668 | 168,768 | 2024-11-04 | Filing | ||
| $0.35 | 4,149 | 172,436 | 2024-08-01 | Filing | ||
| $0.75 | 3,936 | 176,585 | 2024-05-02 | Filing | ||
| $0.83 | 2,753 | 53,365 | 2024-04-05 | Filing | ||
| $0.83 | 2,753 | 88,247 | 2024-04-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,554,258 | $2,640,814 | 0% | |
| 2. | 2,631,067 | $1,954,882 | 0% | |
| 3. | 1,812,100 | $1,346,390 | 0.02% | |
| 4. | 1,020,878 | $758,512 | 0% | |
| 5. | 1,008,959 | $749,738 | 0% |
News See All
Cara Therapeutics, Inc. (NASDAQ:CARA) Q3 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Latif and I will be your conference facilitator.
Cara Therapeutics, Inc. (NASDAQ:CARA) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by, and welcome to Cara Therapeutics' Second Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. [Operator Instructions].
Cara Therapeutics, Inc. (NASDAQ:CARA) Q1 2023 Earnings Call Transcript
Operator: Good afternoon. My name is Lateef, and I will be your conference facilitator.
Cara Therapeutics, Inc. (NASDAQ:CARA) Q4 2022 Earnings Call Transcript
Operator: Good afternoon. My name is Josh, and I will be your conference facilitator.
5 Medical Marijuana Stocks to Buy Now
In this article, we discuss 5 medical marijuana stocks to invest in.
10 Best CBD Stocks To Invest In
With the growing acceptance of cannabis among global consumers and their elected representatives, the CBD market has experienced vast growth due to an increase in sales, legalization, and medical and ...
Top 10 Stocks to Invest in Based on Traci Lerner’s Chescapmanager LLC's Portfolio
In this article, we discuss the top 10 stocks to invest in based on Traci Lerner’s Chescapmanager LLC's portfolio.
5 Best CBD Stocks to Invest In
In this article, we will be looking at the 5 best CBD stocks to invest in.
Were Hedge Funds Right About Cara Therapeutics Inc (CARA)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.